80 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48)PO, DAILY

160 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY

320 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY

640 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY

1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, DAILY

2560 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

18 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

36 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

72 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

144 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

288 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

576 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

750mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

1000mg/m2 PO Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

1280 mg/m2 Camptothecin-20-O-Propionate Hydrate (CZ48) PO, TID

Advanced Solid Tumors

Lymphomas

CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.

Camptothecin-20-O-Propionate Hydrate (CZ48)

University of Texas Health Sciences Center

camptotheca/lymphoma

Phase I and Pharmacology Study of Camptothecin-20-O-Propionate Hydrate (CZ48) in Patients With Solid Tumors or Lymphoma

Elm tərəfindən dəstəklənən ən tam dərman bitkiləri bazası